PreciseDx Joins Leading Voices on AI Drug Discovery at NYC Summit
PreciseDx will participate in the NYC Leadership Summit panel on AI-driven drug discovery, with Vijay Yadav, VP of AI & Technology, representing the company. The session brings together senior representatives from Kyowa Kirin, Memorial Sloan Kettering Cancer Center and AstraZeneca to frame near-term opportunities and practical limits for artificial intelligence in therapeutics and diagnostics.
Panel Addresses AI’s Impact, Regulation, and Innovation
Industry Leaders Converge
The lineup mixes pharma, academic oncology and AI-first diagnostics, reflecting a shift from proof of concept toward clinical and commercial integration. Panel topics are expected to include validation standards, data sharing for model training, trial design that uses AI-derived biomarkers, and the regulatory pathways companies must pursue for clinical deployment.
PreciseDx’s Contribution to Precision Oncology
PreciseDx will highlight PreciseBreast as an example of an applied AI tool for oncology diagnostics and clinical decision support. Tools like PreciseBreast illustrate how algorithmic phenotyping and pathology-driven signals can inform patient selection for trials, accelerate biomarker identification, and provide clinicians with interpretable outputs for care decisions when properly validated.
Shaping the Future of Personalized Medicine
The summit conversation matters because it maps where investment, research and regulation intersect. Attendees will discuss requirements for clinical validation, the role of real-world evidence, and governance measures that preserve patient safety while allowing iterative model improvement. Progress in those areas determines how quickly AI can move from pilot projects to standard practice.
Strategic Implications for Healthcare Innovation
For companies like PreciseDx, participation signals readiness to engage with partners and regulators on shared standards. For investors and health systems, the dialogue offers a view into which technologies are most likely to scale. The summit is a practical forum where technical capability, clinical utility and compliance obligations are weighed together, shaping next steps for AI drug discovery and precision medicine.
